Close
Help




JOURNAL

Clinical Medicine Insights: Cardiology

258,691 Journal Article Views | Journal Analytics

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform

Submit a Paper



Publication Date: 23 Jul 2013

Type: Review

Journal: Clinical Medicine Insights: Cardiology

Citation: Clinical Medicine Insights: Cardiology 2013:7 115-126

doi: 10.4137/CMC.S11516

Abstract

Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform.


Downloads

PDF  (1.68 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Cardiology
The review process in Libertas Academica journals is prompt, objective and rigorous.  The entire process is smooth and clear and all the editorial staff are cooperative and professional.  Published papers are of top clinical and scientific value, and high metrics reflect the excellent quality of Libertas Academica's journals.
Dr Antoine Kossaify (USEK NDS University Hospital, Byblos, Lebanon)
More Testimonials

Quick Links


New article and journal news notification services